• English
    • svenska
  • svenska 
    • English
    • svenska
  • Logga in
Redigera dokument 
  •   Startsida
  • Sahlgrenska Academy / Sahlgrenska akademin
  • Institute of Clinical Sciences / Institutionen för kliniska vetenskaper
  • Doctoral Theses / Doktorsavhandlingar Institutionen för kliniska vetenskaper
  • Redigera dokument
  •   Startsida
  • Sahlgrenska Academy / Sahlgrenska akademin
  • Institute of Clinical Sciences / Institutionen för kliniska vetenskaper
  • Doctoral Theses / Doktorsavhandlingar Institutionen för kliniska vetenskaper
  • Redigera dokument
JavaScript is disabled for your browser. Some features of this site may not work without it.

Prognostic factors and tumor treatments in hepatocellular cancer

Sammanfattning
Background: Hepatocellular carcinoma (HCC) is one of the most common causes of cancer-related death worldwide. Prognosis is related to tumor burden, liver function, and performance status as well as treatment factors. Accurate prognostication is a requisite for optimal treatment decisions. Aims: The general aim was to explore specific prognostic factors in different settings of HCC, and to evaluate outcome after treatment with curative intent in patients eligible for multiple treatments. Methods: This thesis is based on four clinical studies in patients with HCC. Study I is a prospective observational study, investigating if patient-reported quality of life (QoL) can predict survival and increase the prognostic accuracy of established staging models. Study II is a review of medical records in a national cohort of patients with liver transplantation from 1996-2014, investigating if AFP levels increase the prognostic accuracy of current selection criteria. Study III is a prospective feasibility study, evaluating neo-adjuvant systemic treatment with sorafenib before liver transplantation. In the fourth study, data from a national registry 2008-2016, was used to assess risk factors and compare outcome in patients eligible for multiple treatments. Overall and recurrence-free survival rates were estimated using Kaplan-Meier and comparisons using log rank tests. Risk factor assessment was performed using Cox Regression analyses. Results and Conclusions: QoL data was prognostic for survival. Adding QoL data improved the prognostic accuracy of established scoring systems. Pre-transplant AFP was a prognostic factor for survival after liver transplantation for HCC. AFP combined with traditional criteria improved the accuracy of patient selection. Sorafenib treatment before liver transplantation was associated with low tolerability and inadequate tumor control. Survival differences after liver transplantation, resection, or ablation were limited in subgroups with well-preserved liver function and limited tumor burden. Liver function variables predicted survival and should be carefully considered in treatment decisions.
Delarbeten
I. Sternby Eilard, M, Hagström, H, Mortensen, KE, Wilsgaard, T, Vagnildhaug O M, Dajani, O, Stål, P, Rizell, M. Quality of life as a prognostic factor for survival in hepatocellular carcinoma. Liver International 2018; 38(5): 885-894. ::doi::10.1111/liv.13593
 
II. Sternby Eilard, M, Holmberg, E, Naredi, P, Söderdahl, G, Rizell, M. Addition of alfa fetoprotein to traditional criteria for hepatocellular carcinoma improves selection accuracy in liver transplantation. Scandinavian J Gastroenterology 2018; 53(8):976-983 ::doi::10.1080/00365521.2018.1488180
 
III. Sternby Eilard, M, Andersson, M, Naredi, P, Geronymakis, C, Lindnér, P, Cahlin, C, Bennet, W, Rizell, M. A prospective clinical trial on sorafenib treatment of hepatocellular carcinoma before liver transplantation. Submitted.
 
IV. Sternby Eilard, M, Naredi, P, Helmersson, M, Hemmingsson, O, Isaksson, B, Lindell G, Sandström, P, Strömberg, C, Rizell, M. Survival outcome after liver transplantation versus resection and ablation for early HCC - a national registry based study. Submitted.
 
Examinationsnivå
Doctor of Philosophy (Medicine)
Universitet
University of Gothenburg. Sahlgrenska Academy
Institution
Institute of Clinical Sciences. Department of Surgery
Disputation
Fredagen den 29 mars 2019, kl. 13.00, Hörsal Arvid Carlsson, Academicum, Medicinaregatan 3, Göteborg
Datum för disputation
2019-03-29
E-post
malin.sternby.eilard@gu.se
URL:
http://hdl.handle.net/2077/58490
Samlingar
  • Doctoral Theses / Doktorsavhandlingar Institutionen för kliniska vetenskaper
  • Doctoral Theses from Sahlgrenska Academy
  • Doctoral Theses from University of Gothenburg / Doktorsavhandlingar från Göteborgs universitet
Fil(er)
Thesis frame (31.03Mb)
Abstract (113.2Kb)
Datum
2019-03-04
Författare
Sternby Eilard, Malin
Nyckelord
hepatocellular cancer
prognostication
Publikationstyp
Doctoral thesis
ISBN
978-91-7833-320-2 (print)
978-91-7833-321-9 (PDF)
Språk
eng
Metadata
Visa fullständig post

DSpace software copyright © 2002-2016  DuraSpace
gup@ub.gu.se | Teknisk hjälp
Theme by 
Atmire NV
 

 

Visa

VisaSamlingarI datumordningFörfattareTitlarNyckelordDenna samlingI datumordningFörfattareTitlarNyckelord

Mitt konto

Logga inRegistrera dig

DSpace software copyright © 2002-2016  DuraSpace
gup@ub.gu.se | Teknisk hjälp
Theme by 
Atmire NV